Genmab to Hold 2024 R&D Update and ASH Data Review Meeting
11 déc. 2024 08h20 HE
|
Genmab A/S
Media Release Event to be held virtually via live webcast and archived on www.genmab.com Copenhagen, Denmark; December 11, 2024 – Genmab A/S (Nasdaq: GMAB) will hold its 2024 R&D Update and ASH...
Two Data Analyses from Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable, Complete Responses as Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma (DLBCL)
09 déc. 2024 12h00 HE
|
Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; December 9, 2024 Results from Arm 1 of the EPCORE® NHL-2 trial show treatment with epcoritamab combination led to an overall response rate (ORR) of 100 percent and a...
Investigational Epcoritamab (DuoBody® CD3xCD20) Monotherapy Achieves High Overall and Complete Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) in Preliminary Analysis
08 déc. 2024 11h00 HE
|
Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; December 8, 2024 Preliminary analyses from the EPCORE® CLL-1 trial demonstrates overall response rate (ORR) of 61 percent and complete response (CR) rate of 39...
Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Therapy Demonstrates High Response Rates in Clinical Trial of Patients With Relapsed or Refractory (R/R) Follicular Lymphoma (FL)
07 déc. 2024 19h12 HE
|
Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; December 7, 2024 Results show 96 percent overall response rate (ORR), 87 percent complete response (CR), and 80 percent 21-month progression-free survival (PFS) in...
Capital Increase in Genmab as a Result of Employee Warrant Exercise
03 déc. 2024 16h35 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; December 3, 2024 – Genmab A/S (Nasdaq: GMAB) will increase its share capital by 10,355 shares as a consequence of the exercise of employee warrants. The...
Transactions With Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons
03 déc. 2024 07h07 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; December 3, 2024 – Genmab A/S (Nasdaq: GMAB) – In accordance with Article 19 of Regulation No. 596/2014 on Market Abuse and Implementing Regulation...
Genmab to Present at Citi’s Global Healthcare Conference
25 nov. 2024 11h06 HE
|
Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; November 25, 2024 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano will take part in a fireside chat at Citi’s 2024 Global...
Grant of Restricted Stock Units and Warrants to Employees in Genmab
21 nov. 2024 14h48 HE
|
Genmab A/S
Company Announcement COPENHAGEN, Denmark; November 21, 2024 – Genmab A/S (Nasdaq: GMAB) announced today that the Board decided to grant 10,273 restricted stock units and 10,853 warrants to employees...
Genmab Announces Financial Results for the First Nine Months of 2024
06 nov. 2024 11h02 HE
|
Genmab A/S
November 6, 2024 Copenhagen, Denmark; Interim Report for the First Nine Months Ended September 30, 2024 Highlights European Commission (EC) granted conditional marketing authorization for TEPKINLY®...
Genmab to Present at Jefferies London Healthcare Conference
05 nov. 2024 13h11 HE
|
Genmab A/S
Media ReleaseCOPENHAGEN, Denmark; November 5, 2024 Genmab A/S (Nasdaq: GMAB) announced today that its Chief Executive Officer, Jan van de Winkel, Ph.D. and Chief Financial Officer, Anthony...